Scott I. Abrams

Roswell Park Comprehensive Cancer Center — United States

Immunology and Microbiology · Life Sciences

52h-index11.0kcitations423works0.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(140), Immune cells in cancer(114), Cancer Immunotherapy and Biomarkers(98), Immune Cell Function and Interaction(66), Cancer Research and Treatments(45)

Publications423 total

Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer
npj Breast Cancer·2025Open Access
693 A novel tri-therapy overcoming immune suppression, immune exhaustion, and low antigen-specific T cell infiltration elicits robust antitumor responses
Regular and Young Investigator Award Abstracts·2025Open Access
p38 blockade reverses the immune suppressive tumor microenvironment in metastatic breast cancer
2025Open Access
ASO Visual Abstract: ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in ER-Positive HER2-Negative Breast Cancer
Annals of Surgical Oncology·2025
BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer
Molecular Therapy·2025· 1 citedOpen Access
ASO Author Reflections: Predictors of Immune Checkpoint Inhibitor Response in ER+/HER2– Breast Cancer: A New Role for ESR1?
Annals of Surgical Oncology·2025
ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in Estrogen Receptor-Positive/HER2-Negative Breast Cancer
Annals of Surgical Oncology·2025· 3 cited
Association and Prognostic Significance of Comorbidities in Individuals With MGUS
Clinical Lymphoma Myeloma & Leukemia·2025
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma
Cancer Cell·2025· 4 citedOpen Access
ASO Author Reflections: Reframing Hippo Pathway Activation as a Prognostic and Predictive Biomarker in HER2-Positive Breast Cancer
Annals of Surgical Oncology·2025
Activated Hippo Pathway is Associated with a Worse Response to Trastuzumab and Worse Survival in HER2-Positive Breast Cancer
Annals of Surgical Oncology·2025· 3 cited
Abstract P3-08-27: Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer
Clinical Cancer Research·2025
p38 blockade reverses the immune suppressive tumor microenvironment in metastatic breast cancer
2025Open Access
Abstract 2283: Ancestral and genetic determinants of pathologic tumor infiltrating lymphocytes in a large multi-ethnic population of women with breast cancer
Cancer Research·2025
Abstract 663: A novel combination immunotherapy for p53 mutant metastatic breast cancer leveraging vulnerabilities in the DNA damage response
Cancer Research·2025
Obesity-Mediated Intratumoral Innervation Increases Pancreatic Cancer Tumorigenesis
SSRN Electronic Journal·2025Open Access
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
EMBO Reports·2024· 3 citedOpen Access
Abstract PR006: Arginine dependent immuno-metabolic reprogramming by metabolic enzyme PFKFB4 underpins breast tumor immune tolerance
Cancer Research·2024
Differences in Immune Cell Populations between Individuals with or without MGUS
Blood·2024· 1 citedOpen Access
Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer
2024Open Access
page 1 of 22Next →

Frequent Co-authors

Jeffrey Schlom(12), Kebin Liu(7), James W. Hodge(6), Judy Kantor(5), Jeremy D. Waight(4), Elizabeth A. Repasky(4), Kunle Odunsi(4), Dafeng Yang(3), Brahm H. Segal(3), Bonnie L. Hylander(3), Austin Miller(3), Cameron R. MacDonald(3), Michelle N. Messmer(3), Song Liu(3), Elmina Mammadova‐Bach(3), Elke S. Bergmann‐Leitner(3), Jason B. Muhitch(3), Sheila A. Caldwell(2), Mala Chakraborty(2), Kevin Camphausen(2)